Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.
about
Tacrolimus (FK506) for induction of remission in refractory ulcerative colitisTacrolimus for the Treatment of Ulcerative ColitisTacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational studyOn the action of cyclosporine A, rapamycin and tacrolimus on M. avium including subspecies paratuberculosisGuideline adherence and patient satisfaction in the treatment of inflammatory bowel disorders--an evaluation study.Current approaches to the management of new-onset ulcerative colitis.Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis.Infliximab: the evidence for its place in therapy in ulcerative colitis.Management of acute severe ulcerative colitis.Current treatment of ulcerative colitisInfliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study.MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE.EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus.Drug safety in Crohn's disease therapy.Biotic acts of antibioticsThe Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic ScoreTreatment of severe steroid refractory ulcerative colitis.Therapeutic options in acute severe ulcerative colitis.The Asia-Pacific consensus on ulcerative colitis.Targeting signaling pathways with small molecules to treat autoimmune disorders.Renal manifestations and complications of inflammatory bowel disease.The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease.Review article: the role of non-biological drugs in refractory inflammatory bowel disease.Novel topical therapies for distal colitis.Systematic review: the role of tacrolimus in the management of Crohn's disease.Readministration of calcineurin inhibitors for ulcerative colitis.Oral tacrolimus as maintenance therapy for refractory ulcerative colitis--an analysis of outcomes in two London tertiary centres.Ulcerative colitis: prevention of relapse.Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents.What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis.Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use.A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis.Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis.Tacrolimus Therapy for Ulcerative Colitis-Associated Post-Colectomy Enteritis.Tacrolimus (FK506): Safety and Applications in Reconstructive Surgery.Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study.
P2860
Q24242681-836DB8F9-AFBC-4D14-A76E-8B138D310DFEQ26997361-B733C1FF-978B-4DFF-8E4A-1C40E7ECAFD1Q31004717-32897B30-CD48-4A6A-B8DD-B1936A18DB8FQ33346257-C1052F79-7CF6-4107-84BF-CEBFD8AD7485Q33403401-D5227BB7-9802-4A50-9994-96B7A8072225Q33633288-46390967-3886-4897-A335-0D7DB226B96AQ34098754-E8FC4027-ADD8-4754-BFB8-A53893E85CB1Q34213109-4ADC08F1-3559-4480-A713-27960C470186Q34449876-9B865F45-7D16-4710-807E-41D4B3998730Q34508900-7BD466CE-894F-4251-B18A-53542A81C80EQ35171533-B4B7B059-5529-40D0-A27D-8EF1E3FF12C3Q36037115-CCDF7340-2719-4FFB-8130-3315735AD3D9Q36167512-B36207DE-59C6-4D73-8227-75783B6F795CQ36317757-58910F78-2503-4274-BC87-CE5D89DD195EQ36830507-5F1CB9E8-EDB4-486A-8B58-39186ED21AA1Q37073426-DB93CA7B-402E-4DE0-BC66-353200AA9C2AQ37101851-ECD49A6D-5B8D-430C-929E-E43CA43CF540Q37118462-7494D28E-5112-4995-974E-6D0800E73616Q37276958-138CC756-2F08-4852-917C-E5C266C70756Q37345935-AAE6A476-E7B5-47A7-B795-45E455B971A2Q37725083-1C54E874-8629-4D54-813F-D6A2DBCCAA1DQ37755216-4EB21960-9B39-4182-83BB-EB611B19FC7AQ37789000-5D7D8172-F20F-458C-8780-D3DC406F5E42Q37816246-2627DF37-DE6B-4A04-8CD0-5E6DF93441ACQ37817487-1C2FECAE-A035-433A-9DE9-BE900A5BD614Q37876204-6F760DF1-2554-419A-90AA-4F71066A97A1Q37945747-AAC8A6E1-F726-423C-AC23-BC1D2E128F92Q38049067-17F96539-EF80-4DED-9DEC-6201BD37CAECQ38102458-B83AB705-D4B8-4DA4-8BB1-C4FD0DE2E13AQ38103628-803E3A10-93E0-4B50-B7C8-EB34AAC03DF0Q38136748-3278B9C9-7373-484C-A020-43277C121CFEQ38191583-06F9D8BF-86B2-4F05-93B5-0959CC61CD15Q38204993-0027AA54-C918-47BD-863E-7BF5C1279141Q38230163-D5BB97DB-36A8-4D65-B1C0-4007BAF48D64Q38287132-F80DB9B8-B4BC-4946-9DFE-D3C9DD85A884Q38460376-F5785650-49D5-4AC7-BBC6-ACE08DE2B7A4Q38662186-B611F1A7-2F72-4AAE-9D7D-F05F39DF263FQ40778731-993DEFBD-AFF7-4B5E-B8ED-E9372189960FQ42056355-CDDECD7E-1991-4064-851B-D33661162222Q42280471-8B8ABA26-BC4C-4869-B214-01452597D17E
P2860
Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Tacrolimus is safe and effecti ...... isease--a long-term follow-up.
@ast
Tacrolimus is safe and effecti ...... isease--a long-term follow-up.
@en
Tacrolimus is safe and effecti ...... isease--a long-term follow-up.
@nl
type
label
Tacrolimus is safe and effecti ...... isease--a long-term follow-up.
@ast
Tacrolimus is safe and effecti ...... isease--a long-term follow-up.
@en
Tacrolimus is safe and effecti ...... isease--a long-term follow-up.
@nl
prefLabel
Tacrolimus is safe and effecti ...... isease--a long-term follow-up.
@ast
Tacrolimus is safe and effecti ...... isease--a long-term follow-up.
@en
Tacrolimus is safe and effecti ...... isease--a long-term follow-up.
@nl
P2093
P2860
P921
P1476
Tacrolimus is safe and effecti ...... isease--a long-term follow-up.
@en
P2093
Andreas Sturm
Axel U Dignass
Daniel C Baumgart
Jan P Pintoffl
P2860
P304
P356
10.1111/J.1572-0241.2006.00524.X
P407
P577
2006-05-01T00:00:00Z